person · Reporting owner

Parker Geoffrey M.

Disclosed activity across 7 companies

Tapewire entity: 37676
SEC CIK: 0001491874

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allogene Therapeutics, Inc.ALLO · Entity 5243	CHIEF FINANCIAL OFFICER	February 02, 2026	February 04, 2026
Better Therapeutics, Inc.BTTX · Entity 94385	Director	December 18, 2023	December 20, 2023
PERRIGO Co plcPRGO · Entity 4516	Director	September 11, 2026	September 15, 2026
Tricida, Inc.TCDA · Entity 122050	COO, CFO and EVP	February 28, 2022	March 02, 2022
Viracta Therapeutics, Inc.SNSS · Entity 85616	Director	May 31, 2017	June 02, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allogene Therapeutics, Inc.

Report date February 02, 2026 · Filed February 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,252,795	Reported balance After 2026-02-02 transaction · row 1 1 source row Row 1 · 2026-02-02 · Sale · Disposed 24,001 · Balance 1,252,795 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-02-02	Direct	539,072	Reported balance After 2026-02-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-02 · Grant · Acquired 539,072 · Balance 539,072 F3: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	152,480	Reported balance After 2026-02-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-02 · Grant · Acquired 152,480 · Balance 152,480 F4: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

F4: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Better Therapeutics, Inc.

Report date December 18, 2023 · Filed December 20, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,031,805	Reported balance After 2023-12-18 transaction · row 1 1 source row Row 1 · 2023-12-18 · Grant · Acquired 3,750 · Balance 1,031,805 F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.
Common StockSEC Table I · non-derivative	IndirectBy Parker Trust	53,333	Reported balance Holding disclosure · report date 2023-12-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 53,333 F2: These shares are owned directly by the Geoffrey M. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.

F2: These shares are owned directly by the Geoffrey M. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust.

PERRIGO Co plc

Report date September 11, 2026 · Filed September 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	33,873	Ending reported balance After 2026-09-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-11 · Exercise / conversion · Acquired 1,263 · Balance 34,480 Row 2 · 2026-09-11 · Tax withholding · Disposed 607 · Balance 33,873
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-09-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-11 · Exercise / conversion · Disposed 1,263 · Balance 0 F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026.
Ordinary SharesSEC Table I · non-derivative	IndirectRevocable Trust	25,879	Reported balance Holding disclosure · report date 2026-09-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 25,879 F1: Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.
Ordinary SharesSEC Table I · non-derivative	IndirectIRA	17,375	Reported balance Holding disclosure · report date 2026-09-11 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 17,375 F2: Geoffrey M. Parker Roth IRA.

Filing footnotes · ownership attribution and instrument terms

F1: Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.

F2: Geoffrey M. Parker Roth IRA.

F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F4: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026.

Tricida, Inc.

Report date February 28, 2022 · Filed March 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2032-02-27	Direct	256,000	Reported balance After 2022-02-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-02-28 · Grant · Acquired 256,000 · Balance 256,000 F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on February 28, 2023, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on February 28, 2023, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date.

Viracta Therapeutics, Inc.

Report date May 31, 2017 · Filed June 02, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2027-05-31	Direct	25,000	Reported balance After 2017-05-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-31 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests over one (1) year in equal monthly installments from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over one (1) year in equal monthly installments from the date of grant.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ChemoCentryx, Inc.

Report date October 20, 2022 · Filed October 24, 2022

Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-20 transaction · row 1 1 source row Row 1 · 2022-10-20 · Disposition to issuer · Disposed 107,997 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Common StockSEC Table I · non-derivative	IndirectGeoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust	Reported balance After 2022-10-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-20 · Disposition to issuer · Disposed 21,076 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Common StockSEC Table I · non-derivative	IndirectBy Delaware Charter Guarantee & Trust Company, Trustee FBO Mr. Geoffrey Monroe Parker IRA	Reported balance After 2022-10-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.39	Direct	Reported balance After 2022-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-20 · Disposition to issuer · Disposed 8,342 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06	Direct	Reported balance After 2022-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60	Direct	Reported balance After 2022-10-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.94	Direct	Reported balance After 2022-10-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-20 · Disposition to issuer · Disposed 13,352 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.94	Direct	Reported balance After 2022-10-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-20 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-20 · Disposition to issuer · Disposed 15,723 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,

F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.

F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

GENOMIC HEALTH INC

Report date November 08, 2019 · Filed November 14, 2019

Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-08 transaction · row 1 1 source row Row 1 · 2019-11-08 · Grant · Disposed 955 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.07 · Expires 2026-06-21	Direct	Reported balance After 2019-11-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $335,468 and 5,494 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the terms of the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16	Direct	Reported balance After 2019-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07	Direct	Reported balance After 2019-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14	Direct	Reported balance After 2019-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.

F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $335,468 and 5,494 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the terms of the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F5: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 13, 2018 Filed Nov 13, 2018 23:54 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	5,000	$29.72	$148,600.00	Disclosure SEC source: 0001595585-18-000020 · wf-form4_154215325031921.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Chief Fin. Officer and Sr. VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Read SEC document
November 12, 2018 Filed Nov 13, 2018 11:15 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	3,000	$65.35	$196,058.10	Disclosure SEC source: 0001585364-18-000097 · wf-form4_154210773935262.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 5,500 F1 · price: Price is a weighted average. Actual priced received ranged from $65.19-$65.48. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Geoffrey M. Parker Roth IRA. Read SEC document
July 02, 2018 Filed Jul 3, 2018 00:48 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	60,000	$19.00	$1,140,000.00	Disclosure SEC source: 0001140361-18-031039 · form4.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Chief Fin. Officer and Sr. VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Read SEC document
June 07, 2018 Filed Jun 11, 2018 19:52 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GrantDirector Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $51.72	$0.00	Disclosure SEC source: 0001209191-18-037123 · doc4.xml · derivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option becomes fully vested in the event of a change in control of the Company. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	4,265	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-18-000047 · wf-form4_152849272890760.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	2,048	$73.22	$149,954.56	Disclosure SEC source: 0001585364-18-000047 · wf-form4_152849272890760.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	4,265	$73.22	$312,283.30	Disclosure SEC source: 0001585364-18-000047 · wf-form4_152849272890760.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on June 6, 2017. Read SEC document
May 25, 2018 Filed May 30, 2018 21:13 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	12,912	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-034195 · doc4.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vested on May 25, 2018. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units vested on May 25, 2018. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document
May 25, 2018 Filed May 30, 2018 21:13 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	12,912	$0.00	$0.00	Disclosure SEC source: 0001209191-18-034195 · doc4.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 25, 2017. Read SEC document
May 21, 2018 Filed May 24, 2018 01:50 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantStock Option (Right to buy) · Derivative	13,352	$0.00 Strike: $12.94	$0.00	Disclosure SEC source: 0001209191-18-032801 · doc4.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,352 Underlying: Common Stock · 13,352 shares Expires 2028-05-21 F3 · derivative.exercise_date: The option was granted on May 21, 2018. The award vests and becomes exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Read SEC document
May 21, 2018 Filed May 24, 2018 01:50 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantRestricted Stock Units · Derivative	8,421	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-032801 · doc4.xml · derivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,421 Underlying: Common Stock · 8,421 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on May 21, 2018 vests on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F2 · derivative.expiration_date: The restricted stock units awarded on May 21, 2018 vests on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document
May 15, 2018 Filed May 17, 2018 20:19 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	3,971	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-18-000034 · wf-form4_152658829248601.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,971 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	511	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · derivative · entry 8 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · kind: Vesting of service-based restricted stock units granted on November 17, 2016. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F5 · derivative.exercise_date: The earlier of the first anniversary of the grant date or the date of the Issuer's next Annual General Meeting of Shareholders. F5 · derivative.expiration_date: The earlier of the first anniversary of the grant date or the date of the Issuer's next Annual General Meeting of Shareholders. Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	1,437	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · derivative · entry 7 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,437 shares Expires 2017-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · kind: Vesting of service-based restricted stock units granted on June 6, 2017. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	246	$75.51	$18,575.46	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · nonDerivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	511	$75.51	$38,585.61	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · nonDerivative · entry 3 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	690	$75.51	$52,101.90	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747 Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	1,437	$75.51	$108,507.87	Disclosure SEC source: 0001585364-17-000129 · wf-form4_150092965824250.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2017 Filed Jun 20, 2017 20:34 UTC	GENOMIC HEALTH INC GHDX · Entity 153816	GrantDirector Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $31.53	$0.00	Disclosure SEC source: 0001209191-17-041146 · doc4.xml · derivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-16 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option becomes fully vested in the event of a change in control of the Company. Read SEC document
June 06, 2017 Filed Jun 8, 2017 21:46 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	1,437	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000112 · wf-form4_149695837187485.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437 Underlying: Ordinary Shares · 1,437 shares Expires 2017-07-20 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · kind: Represents a prorated award for partial year of Board service. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
June 06, 2017 Filed Jun 8, 2017 21:46 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	4,265	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000112 · wf-form4_149695837187485.xml · derivative · entry 3 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
May 31, 2017 Filed Jun 2, 2017 17:22 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.96	$0.00	Disclosure SEC source: 0001179110-17-008457 · edgar.xml · derivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The option vests over one (1) year in equal monthly installments from the date of grant. Read SEC document
May 26, 2017 Filed May 30, 2017 23:28 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	20,362	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-036290 · doc4.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document
May 26, 2017 Filed May 30, 2017 23:28 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	20,362	$0.00	$0.00	Disclosure SEC source: 0001209191-17-036290 · doc4.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 26, 2016. Read SEC document
May 25, 2017 Filed May 30, 2017 23:28 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantRestricted Stock Units · Derivative	12,912	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-036290 · doc4.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,912 Underlying: Common Stock · 12,912 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document
December 09, 2016 Filed Dec 12, 2016 18:43 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	PurchaseCommon Stock	594	$3.90	$2,317.67	Disclosure SEC source: 0001179110-16-032838 · edgar.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,745 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.79 to $3.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document
December 09, 2016 Filed Dec 16, 2016 17:53 UTC Amendment	Viracta Therapeutics, Inc. SNSS · Entity 85616	PurchaseCommon Stock	594	$3.90	$2,317.67	Disclosure SEC source: 0001179110-16-033153 · edgar.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,074 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.79 to $3.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document
December 08, 2016 Filed Dec 12, 2016 18:43 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	PurchaseCommon Stock	3,146	$3.87	$12,159.29	Disclosure SEC source: 0001179110-16-032838 · edgar.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,151 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.80 to $3.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) of this Form 4. Read SEC document
December 08, 2016 Filed Dec 16, 2016 17:53 UTC Amendment	Viracta Therapeutics, Inc. SNSS · Entity 85616	PurchaseCommon Stock	3,146	$3.87	$12,159.29	Disclosure SEC source: 0001179110-16-033153 · edgar.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,480 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.80 to $3.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) of this Form 4. Read SEC document
November 21, 2016 Filed Nov 21, 2016 20:14 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	2,500	$88.75	$221,875.00	Disclosure SEC source: 0001585364-16-000440 · wf-form4_147975928340136.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 2,500 F1 · price: Price is a weighted average. Actual priced received ranged from $88.81-$88.60. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Geoffrey M. Parker Roth IRA. Read SEC document
November 17, 2016 Filed Nov 18, 2016 16:28 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	511	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-16-000434 · wf-form4_147948648414433.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511 Underlying: Ordinary Shares · 511 shares Expires 2017-05-03 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
November 17, 2016 Filed May 3, 2017 18:35 UTC Amendment	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	511	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000048 · wf-form4a_149383654006817.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511 Underlying: Ordinary Shares · 511 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: The earlier of the first anniversary of the grant date or the date of the Issuer's next Annual General Meeting of Shareholders. F3 · derivative.expiration_date: The earlier of the first anniversary of the grant date or the date of the Issuer's next Annual General Meeting of Shareholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.